Handelsbanken Fonder AB Acquires 18,165 Shares of Bruker Corporation $BRKR

Key Points

• Handelsbanken Fonder increased its Bruker stake by 49.6% in the second quarter, acquiring 18,165 shares for a total position of 54,805 shares valued at approximately $3.3 million. Institutional investors collectively own 79.52% of the company.
• Bruker reported quarterly EPS of $0.49, exceeding estimates of $0.38, while revenue rose 5.2% year over year to $838.5 million, below expectations. The company guided to fiscal 2026 EPS of $2.10–$2.15.
• Analyst sentiment is generally positive, with a current consensus rating of “Moderate Buy” and an average price target of $56.64; however, shares recently opened at $57.70, above that target.

Handelsbanken Fonder AB increased its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 49.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,805 shares of the medical research company's stock after acquiring an additional 18,165 shares during the period. Handelsbanken Fonder AB's holdings in Bruker were worth $3,298,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Orbis Allan Gray Ltd acquired a new position in Bruker during the 2nd quarter valued at about $192,735,000. Price T Rowe Associates Inc. MD raised its stake in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock worth $111,488,000 after purchasing an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock valued at $108,796,000 after purchasing an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Bruker by 222.6% in the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company's stock valued at $86,663,000 after purchasing an additional 1,269,316 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

Shares of BRKR opened at $57.70 on Friday. The stock has a 50 day moving average of $58.36 and a 200 day moving average of $47.05. The company has a market capitalization of $8.79 billion, a price-to-earnings ratio of -82.43, a PEG ratio of 1.76 and a beta of 1.28. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million for the quarter, compared to analysts' expectations of $853.57 million. During the same quarter in the previous year, the firm earned $0.32 earnings per share. The business's revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Analyst Ratings Changes

BRKR has been the subject of several recent research reports. JPMorgan Chase & Co. upped their price target on Bruker from $55.00 to $65.00 and gave the stock an "overweight" rating in a report on Monday, June 8th. Wall Street Zen upgraded Bruker from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. TD Cowen reaffirmed a "hold" rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research assumed coverage on shares of Bruker in a research note on Monday, June 1st. They issued a "peer perform" rating for the company. Finally, Zacks Research upgraded shares of Bruker from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source